Citation Impact
Citing Papers
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance
2003 Standout
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
2009
Ultrasound Increases Nanoparticle Delivery by Reducing Intratumoral Pressure and Increasing Transport in Epithelial and Epithelial–Mesenchymal Transition Tumors
2012
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma
2005
Hepatocellular carcinoma in Central Europe: prognostic features and survival
2001
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
A Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteria
2008
Antitumor activity of photodynamic therapy performed with nanospheres containing zinc-phthalocyanine
2013
Multifunctional Magnetic Nanoparticles for Synergistic Enhancement of Cancer Treatment by Combinatorial Radio Frequency Thermolysis and Drug Delivery
2012
Improved Tumor Destruction with Arsenic Trioxide and Radiofrequency Ablation in Three Animal Models
2006
Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials
2002
A mathematical model to estimate global hepatitis B disease burden and vaccination impact
2005
Hepatocellular carcinoma
2003 Standout
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Multifunctional Lipid/Quantum Dot Hybrid Nanocontainers for Controlled Targeting of Live Cells
2006 StandoutNobel
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
2002 Standout
Radiofrequency Ablation of Liver Cancer
2007
Characteristics of hepatocellular carcinoma in Italy
1998
Hepatocellular carcinoma
2018 Standout
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Association of serum albumin and mortality risk
1997
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Cushing's syndrome
2015 Standout
Screening for hepatocellular carcinoma
1998
Cancer drug resistance: an evolving paradigm
2013 Standout
Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies
2006
Hepatocellular carcinoma
2012 Standout
Mechanisms of Focal Heat Destruction of Liver Tumors
2005
An Analysis of 412 Cases of Hepatocellular Carcinoma at a Western Center
1999
Porphyrias
2010 Standout
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
2015
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution
1998
Selection Criteria for Repeat Hepatectomy in Patients With Recurrent Hepatocellular Carcinoma
2003
RF ablation with adjuvant therapy: Comparison of external beam radiation and liposomal doxorubicin on ablation efficacy in an animal tumor model
2008
Screening for Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis: A Cost-Utility Analysis
2003
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma
1999
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis
2007
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles
2014
Microbubbles improve the ablation efficiency of extracorporeal high intensity focused ultrasound against kidney tissues
2008
Management of Hepatocellular Carcinoma *
2005 Standout
Thermal ablation of tumours: biological mechanisms and advances in therapy
2014 Standout
Association of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease
1998 Standout
Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors
2001
Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma
2010
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma
2010
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization
2010
Carcinoid A Comprehensive Review
2003
The golden age: gold nanoparticles for biomedicine
2011 Standout
Chemoembolization for hepatocellular carcinoma
2004
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma
2006
Liposomal Doxorubicin Increases Radiofrequency Ablation–induced Tumor Destruction by Increasing Cellular Oxidative and Nitrative Stress and Accelerating Apoptotic Pathways
2010
Fluorescent Nanorods and Nanospheres for Real‐Time In Vivo Probing of Nanoparticle Shape‐Dependent Tumor Penetration
2011 StandoutNobel
Treatment of hepatocellular carcinoma in patients with cirrhosis
1997
Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system
2002
Thermal Ablation of Tumors Using Magnetic Nanoparticles
2002
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors
2007
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
2002 Standout
Update on the treatment of neuroendocrine tumors
2003
Results of Surgical and Nonsurgical Treatment for Small–Sized Hepatocellular Carcinomas: A Retrospective and Nationwide Survey in Japan
2000
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Molecular targeted therapy for carcinoid and islet-cell carcinoma
2007
Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors
2000
Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies
2006
A microbubble agent improves the therapeutic efficiency of high intensity focused ultrasound: a rabbit kidney study
2004
Progression of Alphafetoprotein Before Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: A Critical Factor
2009
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
2000
Mesoporous Materials for Drug Delivery
2007 Standout
Transarterial Chemoembolization of Advanced Liver Metastases of Neuroendocrine Tumors – A Retrospective Single-Center Analysis
2003
Somatostatin Analog Therapy in Treatment of Gastrointestinal Disorders and Tumors
2003
Do Liposomal Apoptotic Enhancers Increase Tumor Coagulation and End-Point Survival in Percutaneous Radiofrequency Ablation of Tumors in a Rat Tumor Model?
2010
Reduced Tumor Growth with Combined Radiofrequency Ablation and Radiation Therapy in a Rat Breast Tumor Model
2005
Molecular therapies and precision medicine for hepatocellular carcinoma
2018
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials
1999
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Medical treatments for hepatocellular carcinoma (HCC): what’s next?
2006
Hepatocellular Carcinoma
2011 Standout
Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity
2008
Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model
2011
The Clavien-Dindo Classification of Surgical Complications
2009 Standout
Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis
2008
Management of hepatocellular cancer
2005
Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies
2006
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
2015
Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature
2010 Standout
Principles of and Advances in Percutaneous Ablation
2011
Hepatocellular carcinoma
2022 Standout
Carcinoid Tumors
1999
Surgery as primary treatment in patients with liver metastases from carcinoid tumors: A retrospective, unicentric study over 13 years
2001
Folate status and the safety profile of antifolates
2002
Complications of radiofrequency coagulation of liver tumours
2002
Hepatocellular Carcinoma
2019 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
2008
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Nanoparticles in Photodynamic Therapy
2015 Standout
Sunitinib: From Rational Design to Clinical Efficacy
2007
Therapeutic Alternatives in Metastatic Neuroendocrine Tumors
1998
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy
2007
Electrosprayed nanoparticles and electrospun nanofibers based on natural materials: applications in tissue regeneration, drug delivery and pharmaceuticals
2014 Standout
Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis
2016
Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant
2021
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
2007 Standout
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
2011
Nanoscale theranostics for physical stimulus-responsive cancer therapies
2015
Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or Doxorubicin
2007
Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials
2010
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
2017 Standout
Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells
2008
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
2015
Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
2008
Surveillance for hepatocellular carcinoma
2014
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
2008 Standout
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**
2021 StandoutNobel
Management of people with early- or very early-stage hepatocellular carcinoma
2017
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas
2004
Works of Keith Stuart being referenced
A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
2013
Hepatic Arterial Chemoembolization for Metastatic Neuroendocrine Tumors
1994
A Phase II Study of Docetaxel in Patients with Metastatic Carcinoid Tumors
2004
Percutaneous Tumor Ablation: Increased Necrosis with Combined Radio-frequency Ablation and Intravenous Liposomal Doxorubicin in a Rat Breast Tumor Model
2002
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
2007
Phase II Study of Gemcitabine in Combination with Docetaxel in Patients with Advanced Pancreatic Carcinoma (E1298)
2004
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
2002
Chemoembolization of Hepatic Neoplasms: Safety, Complications, and When to Worry
1999
Hepatocellular carcinoma in the United States: Prognostic features, treatment outcome, and survival
1996
Preoperative chemoradiation in resectable pancreatic cancer
2003
Radio-frequency Ablation Increases Intratumoral Liposomal Doxorubicin Accumulation in a Rat Breast Tumor Model
2002
A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma
2001
5-Fluorouracil and Alpha-Interferon in Hepatocellular Carcinoma
1996
Percutaneous Tumor Ablation: Increased Necrosis with Combined Radio-Frequency Ablation and Intratumoral Doxorubicin Injection in a Rat Breast Tumor Model
2001
Hepatic chemoembolization: Effect of intraarterial lidocaine on pain and postprocedure recovery
1999
Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization
1993
A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma
1999
Hepatic arterial chemoembolization for metastatic neuroendocrine tumors.
1994
O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
2008
Chemoembolization in the Management of Liver Tumors
2003
A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors
2006
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
2008
Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation.
2003
Percutaneous Tumor Ablation: Reduced Tumor Growth with Combined Radio-frequency Ablation and Liposomal Doxorubicin in a Rat Breast Tumor Model
2003
A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)
2005
A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with hepatocellular carcinoma
2005
Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
2006
Hepatocellular carcinoma in the United States: Prognostic features, treatment outcome, and survival
1996
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
2006
Radiofrequency Ablation of Hepatic Tumors: Increased Tumor Destruction with Adjuvant Liposomal Doxorubicin Therapy
2002
Economic analysis of transarterial chemoembolization (TACE) versus stereotactic body radiotherapy (SBRT) for the treatment of hepatocellular carcinoma (HCC).
2018